SAGE Investors Get Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Litigation with Schall Law Firm

Schall Law Firm, a national litigation firm focused on shareholder rights litigation, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. (“Sage” or “the Company”) (NASDAQ: SAGE) for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between April 12, 2021 and July 23, 2024, inclusive (the “Class Period”), are encouraged to contact the Firm before October 28, 2024.